RxDoctor Payments Data

Ajit Sandhu, MD

Pulmonary Disease · Fremont, CANPI 1306953724

Payments from drug & device makers

$1,470in general payments, 2019–2025

Across 24 payments — averaging $61.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$369
  • Novo Nordisk$328
  • Johnson & Johnson$192
  • GSK$150
  • Mallinckrodt Hospital Products Inc.$122
  • Amgen$92
  • plus $216 from 5 others

What the payments were for

  • Food & beverage$1,45399%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,470 in reported general payments places this provider in the 50th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$186,130
Medicare patients
339
Services billed
1,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$53,506
JanuviaSitagliptin Phosphate35$46,983
Breo ElliptaFluticasone/Vilanterol37$13,027
Arnuity ElliptaFluticasone Furoate53$12,911
Albuterol Sulfate HfaAlbuterol Sulfate374$12,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,587
Combivent RespimatIpratropium/Albuterol Sulfate15$7,421
Fluticasone Propionate HfaFluticasone Propionate17$6,874
Qvar RedihalerBeclomethasone Dipropionate19$5,277
Pulmicort FlexhalerBudesonide17$5,191
Advair HfaFluticasone Propion/Salmeterol12$4,649
SymbicortBudesonide/Formoterol Fumarate12$3,673
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,522
Wixela InhubFluticasone Propion/Salmeterol28$2,840
Atorvastatin Calcium379$2,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Arnuity Ellipta, Trelegy Ellipta$150$36,525107 claims
Boehringer IngelheimCombivent Respimat$369$7,42115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Fremont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →